Discussion
PharmaMar has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the use of Aplidin (plitidepsin) in combination with Decadron (dexamethasone, an…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Discussion
Discussion
The Multiple Myeloma Research Foundation (MMRF) and the Memorial Sloan Kettering Cancer Center are collaborating to launch a new clinical trial studying minimal…
Discussion
The association between excess body fat and increased risk of various cancers is an undisputed fact. Now, the findings of a working group from the International…
Discussion
Minimal residual disease, a measurement that shows a low level of disease detected, should be used as an endpoint in myeloma clinical trials, a study…
Discussion
Janssen Biotech has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand Darzalex (daratumumab) to include…
Discussion
Patients with heavily treated multiple myeloma have promising response rates when treated with a combination of selinexor (KPT-330) and low-dose dexamethasone, according to the results…
